Theravance Biopharma, Inc. (FRA:0TB)

Theravance Biopharma Statistics

Total Valuation

FRA:0TB has a market cap or net worth of EUR 854.77 million. The enterprise value is 606.93 million.

Market Cap	854.77M
Enterprise Value	606.93M

Important Dates

The next estimated earnings date is Monday, February 23, 2026.

Earnings Date	Feb 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	50.67M
Shares Outstanding	n/a
Shares Change (YoY)	+3.49%
Shares Change (QoQ)	+2.33%
Owned by Insiders (%)	7.19%
Owned by Institutions (%)	47.85%
Float	22.35M

Valuation Ratios

The trailing PE ratio is 34.18 and the forward PE ratio is 46.97.

PE Ratio	34.18
Forward PE	46.97
PS Ratio	12.49
PB Ratio	4.31
P/TBV Ratio	4.31
P/FCF Ratio	4.12
P/OCF Ratio	4.12
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	24.27
EV / Sales	8.78
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	2.92

Financial Position

The company has a current ratio of 9.48, with a Debt / Equity ratio of 0.19.

Current Ratio	9.48
Quick Ratio	9.30
Debt / Equity	0.19
Debt / EBITDA	n/a
Debt / FCF	0.18
Interest Coverage	-13.01

Financial Efficiency

Return on equity (ROE) is 14.03% and return on invested capital (ROIC) is -8.08%.

Return on Equity (ROE)	14.03%
Return on Assets (ROA)	-5.32%
Return on Invested Capital (ROIC)	-8.08%
Return on Capital Employed (ROCE)	-8.68%
Revenue Per Employee	705,801
Profits Per Employee	257,834
Employee Count	97
Asset Turnover	0.21
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:0TB has paid 15.25 million in taxes.

Income Tax	15.25M
Effective Tax Rate	37.88%

Stock Price Statistics

The stock price has increased by +95.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+95.43%
50-Day Moving Average	13.14
200-Day Moving Average	10.27
Relative Strength Index (RSI)	80.39
Average Volume (20 Days)	31

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	12.21

Income Statement

In the last 12 months, FRA:0TB had revenue of EUR 68.46 million and earned 25.01 million in profits. Earnings per share was 0.49.

Revenue	68.46M
Gross Profit	34.79M
Operating Income	-27.97M
Pretax Income	40.26M
Net Income	25.01M
EBITDA	-26.56M
EBIT	-27.97M
Earnings Per Share (EPS)	0.49

Balance Sheet

The company has 280.99 million in cash and 38.01 million in debt, giving a net cash position of 245.56 million.

Cash & Cash Equivalents	280.99M
Total Debt	38.01M
Net Cash	245.56M
Net Cash Per Share	n/a
Equity (Book Value)	198.31M
Book Value Per Share	3.91
Working Capital	270.43M

Cash Flow

In the last 12 months, operating cash flow was 207.71 million and capital expenditures -190,915, giving a free cash flow of 207.52 million.

Operating Cash Flow	207.71M
Capital Expenditures	-190,915
Free Cash Flow	207.52M
FCF Per Share	n/a

Margins

Gross margin is 50.82%, with operating and profit margins of -40.85% and 36.53%.

Gross Margin	50.82%
Operating Margin	-40.85%
Pretax Margin	58.81%
Profit Margin	36.53%
EBITDA Margin	-38.80%
EBIT Margin	-40.85%
FCF Margin	303.11%

Dividends & Yields

FRA:0TB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.49%
Shareholder Yield	-3.49%
Earnings Yield	2.93%
FCF Yield	24.28%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:0TB has an Altman Z-Score of -0.59 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.59
Piotroski F-Score	6